Replimune Group, Inc. (REPL): Price and Financial Metrics

Replimune Group, Inc. (REPL)

Today's Latest Price: $51.83 USD

1.81 (3.62%)

Updated Nov 27 1:00pm

Add REPL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

REPL Stock Price Chart Interactive Chart >

Price chart for REPL

REPL Price/Volume Stats

Current price $51.83 52-week high $54.85
Prev. close $50.02 52-week low $8.58
Day low $50.00 Volume 101,850
Day high $53.00 Avg. volume 294,073
50-day MA $37.33 Dividend yield N/A
200-day MA $23.25 Market Cap 2.38B

Replimune Group, Inc. (REPL) Company Bio

Replimune Ltd. develops oncolytic immunotherapies for the treatment of cancer. It is developing various proprietary products intended to enhance the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The company was founded in 2015 is based in Abingdon, the United Kingdom.

REPL Latest News Stream

Event/Time News Detail
Loading, please wait...

REPL Latest Social Stream

Loading social stream, please wait...

View Full REPL Social Stream

Latest REPL News From Around the Web

Below are the latest news stories about Replimune Group Inc that investors may wish to consider to help them evaluate REPL as an investment opportunity.

Replimune (REPL) Presents At Wedbush Pacgrow Healthcare Virtual Conference - Slideshow

The following slide deck was published by Replimune Group, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | August 13, 2020

Replimune Appoints Andrea Pirzkall, M.D. as Chief Medical Officer

WOBURN, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the strengthening of its executive team with the appointment of Andrea Pirzkall, M.D. as Replimune’s Chief Medical Officer effective August 31st, 2020. “We are very excited to have Andrea join the Replimune team as we aggressively advance our pipeline,” said Philip Astley-Sparke, Chief Executive Officer of Replimune. “Andrea brings a unique profile and skill set in oncology with a track record of success in advancing cancer drugs through all stages of development, including in immuno-oncology, combined with a multi-disciplinary clinical background prior to moving to industry.”   ...

Yahoo | July 22, 2020

Replimune Group, Inc. (REPL): Hedge Funds Are Reducing Exposure

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]

Yahoo | June 22, 2020

Replimune to Participate at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference

WOBURN, Mass., June 17, 2020 -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform,.

Yahoo | June 17, 2020

Replimune (REPL) Looks Good: Stock Adds 5.8% in Session

Replimune (REPL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Yahoo | June 11, 2020

Read More 'REPL' Stories Here

REPL Price Returns

1-mo 15.25%
3-mo 99.50%
6-mo 175.99%
1-year 281.66%
3-year N/A
5-year N/A
YTD 261.18%
2019 43.50%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6479 seconds.